Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nuvation Bio Inc.NUVB · Entity 4384 | Director | May 21, 2026 | May 27, 2026 |
| Opy Acquisition Corp. IOHAA · Entity 133726 | Director | October 26, 2021 | October 27, 2021 |
| TANDEM DIABETES CARE INCTNDM · Entity 4682 | Director | November 20, 2024 | November 22, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nuvation Bio Inc.
Report date May 21, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.79 · Expires 2036-05-20 | Direct | 123,397 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 123,397 · Balance 123,397 F1: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.
Opy Acquisition Corp. I
Report date October 26, 2021 · Filed October 27, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2021-10-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
TANDEM DIABETES CARE INC
Report date November 20, 2024 · Filed November 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 165,190 |
Last balance in matching sequence
After 2024-11-21 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-11-20 · Sale · Disposed 10,000 · Balance 195,190 F1: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $30.00 to $30.01 F2: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Row 2 · 2024-11-21 · Sale · Disposed 30,000 · Balance 165,190 F3: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $31.22 to $31.63. F2: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $30.00 to $30.01
F2: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010.
F3: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $31.22 to $31.63.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MEDIVATION, INC.
Report date September 28, 2016 · Filed September 30, 2016
Section 16 reporting ended · disclosed 2016-09-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 1
1 source rowRow 1 · 2016-09-28 · Other · Disposed 43,242 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F2: Includes 2,972 unvested shares subject to a restricted stock award. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.21 · Expires 2020-06-30 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-09-28 · Disposition to issuer · Disposed 34,500 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2021-07-15 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-09-28 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.74 · Expires 2022-07-16 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-09-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.60 · Expires 2023-06-28 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-09-28 · Disposition to issuer · Disposed 12,232 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.89 · Expires 2024-06-27 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2016-09-28 · Disposition to issuer · Disposed 9,584 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.45 · Expires 2025-06-16 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2016-09-28 · Disposition to issuer · Disposed 6,284 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.89 · Expires 2026-06-22 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2016-09-28 · Disposition to issuer · Disposed 6,228 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.
F2: Includes 2,972 unvested shares subject to a restricted stock award.
F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 257,000 | $3.50 | $899,500.00 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · nonDerivative · entry 7 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 783,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The transaction reflects the cash exercise of Series A warrants to purchase common stock, at a strike price of $3.50 and a closing market price on the date of exercise of $105.50. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 39,222 | $0.00 Strike: $51.50 | $0.00 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · derivative · entry 23 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,778 Underlying: Common Stock · 39,222 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The option shall vest as to twenty-five percent (25%) of the underlying shares on 02/15/2020, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter. F11 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 39,548 | $0.00 Strike: $11.06 | $0.00 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · derivative · entry 19 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,923 Underlying: Common Stock · 39,548 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The option vested as to twenty-five percent (25%) of the underlying shares on 04/23/2014, and the remaining shares vested in thirty-six (36) equal monthly installments thereafter. F11 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 24,940 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · derivative · entry 18 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,560 Underlying: Common Stock · 24,940 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option vested as to twenty-five percent (25%) of the underlying shares on 05/17/2018, and the remaining shares vested in thirty-six (36) equal monthly installments thereafter. F11 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 16,288 | $11.06 | $180,128.99 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · nonDerivative · entry 6 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 526,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 10,495 | $9.00 | $94,455.00 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · nonDerivative · entry 5 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 510,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 600 | $107.07 | $64,244.52 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · nonDerivative · entry 4 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 500,000 F4 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $107.05 to $107.12. The Reporting Person undertakes to provide the Securitiesand Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 121,698 | $105.65 | $12,856,979.93 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · nonDerivative · entry 3 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 500,600 F3 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $105.50 to $106.25. The Reporting Person undertakes to provide the Securitiesand Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 23,260 | $11.06 | $257,232.34 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 622,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 14,445 | $9.00 | $130,005.00 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 599,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 22:20 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 10,192 | $96.02 | $978,608.32 |
DisclosureSEC source: 0001438133-20-000103 · wf-form4_159372839393327.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 584,593 F1 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2019. F4 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $96.00 and $96.1350. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 22:20 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 39,808 | $95.45 | $3,799,793.02 |
DisclosureSEC source: 0001438133-20-000103 · wf-form4_159372839393327.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 594,785 F1 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2019. F2 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $95.00 and $95.98. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| May 27, 2020 Filed May 30, 2020 00:48 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantRestricted Stock Unit · Derivative | 1,892 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-20-000076 · wf-form4_159079968772006.xml · derivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,892 Underlying: Common Stock · 1,892 shares Expires not disclosed F1 · security: Awarded on May 27, 2020 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan"). F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F3 · derivative.exercise_date: Shares will vest on the one year anniversary of the grant date, subject to the terms of the 2013 Plan. F3 · derivative.expiration_date: Shares will vest on the one year anniversary of the grant date, subject to the terms of the 2013 Plan. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 01:38 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GiftCommon Stock | 7,157 | $70.55 | $504,890.57 |
DisclosureSEC source: 0001438133-20-000021 · wf-form4_158406348959369.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 634,593 F1 · shares: The shares were given as a bona fide gift to BNGF KDB PEORIA WOMEN'S CLUB. F2 · price: The price per share reflects the average of the high and low trading prices of the Company's stock on the transaction date. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 22:22 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 1,488 | $76.33 | $113,579.04 |
DisclosureSEC source: 0001438133-20-000006 · wf-form4_158050930804263.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 641,750 F3 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $76.28 and $76.54. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 22:22 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 48,512 | $75.91 | $3,682,545.92 |
DisclosureSEC source: 0001438133-20-000006 · wf-form4_158050930804263.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 643,238 F1 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $75.29 and $76.25. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| January 29, 2020 Filed Feb 3, 2020 18:00 UTC Amendment | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 1,488 | $76.33 | $113,579.04 |
DisclosureSEC source: 0001438133-20-000010 · wf-form4a_158075284094251.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 641,750 F1 · kind: This amendment is being filed to reflect that the sale was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person dated March 11, 2019. F4 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $76.28 and $76.54. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| January 29, 2020 Filed Feb 3, 2020 18:00 UTC Amendment | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 48,512 | $75.91 | $3,682,545.92 |
DisclosureSEC source: 0001438133-20-000010 · wf-form4a_158075284094251.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 643,238 F1 · kind: This amendment is being filed to reflect that the sale was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person dated March 11, 2019. F2 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $75.29 and $76.25. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 21:26 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 36,738 | $60.60 | $2,226,322.80 |
DisclosureSEC source: 0001438133-19-000032 · wf-form4_157670436312591.xml · nonDerivative · entry 5 BLICKENSTAFF KIM D · CIK 0001238913 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 691,750 F6 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $60.13 and $61.09. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 21:26 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 27,327 | $59.54 | $1,627,049.58 |
DisclosureSEC source: 0001438133-19-000032 · wf-form4_157670436312591.xml · nonDerivative · entry 4 BLICKENSTAFF KIM D · CIK 0001238913 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 728,488 F5 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $59.13 and $60.10. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 21:26 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 35,935 | $58.79 | $2,112,618.65 |
DisclosureSEC source: 0001438133-19-000032 · wf-form4_157670436312591.xml · nonDerivative · entry 3 BLICKENSTAFF KIM D · CIK 0001238913 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 755,815 F4 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $58.13 and $59.12. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 21:26 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 25,000 | $60.93 | $1,523,250.00 |
DisclosureSEC source: 0001438133-19-000032 · wf-form4_157670436312591.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 791,750 F3 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $60.70 and $61.10. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 21:26 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 75,000 | $59.75 | $4,481,250.00 |
DisclosureSEC source: 0001438133-19-000032 · wf-form4_157670436312591.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 816,750 F1 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $59.50 and $60.33. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 20:19 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 80,000 | $71.01 | $5,680,800.00 |
DisclosureSEC source: 0001209191-19-047825 · doc4.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 891,750 F3 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $71.00 and $71.135. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 28, 2019 Filed Aug 30, 2019 20:19 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 20,000 | $70.77 | $1,415,400.00 |
DisclosureSEC source: 0001209191-19-047825 · doc4.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 971,750 F1 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $70.49 and $70.95. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 23:10 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 15,954 | $65.67 | $1,047,699.18 |
DisclosureSEC source: 0001209191-19-019237 · doc4.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 991,750 F3 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $65.51 and $65.795. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 23:10 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 184,046 | $64.89 | $11,942,744.94 |
DisclosureSEC source: 0001209191-19-019237 · doc4.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,007,704 F1 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $64.50 and $65.4925. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 21:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantStock Option · Derivative | 210,000 | $0.00 Strike: $51.50 | $0.00 |
DisclosureSEC source: 0001209191-19-011496 · doc4.xml · derivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires not disclosed F1 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. The grant is contingent upon future stockholder approval of an increase in the number of shares reserved for issuance under the 2013 Stock Incentive Plan. F2 · derivative.exercise_date: The option shall vest as to twenty-five percent (25%) of the underlying shares on 2/15/2020, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter. F3 · derivative.expiration_date: The expiration date for these options is ten (10) years from the date of grant. Read SEC document |
| November 07, 2018 Filed Nov 7, 2018 22:02 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 178,730 | $37.01 | $6,614,636.44 |
DisclosureSEC source: 0001209191-18-057614 · doc4.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,191,750 F2 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $37.00 and $37.205. F1 · ownership.nature: Shares are held by the Kim Blickenstaff Revocable Trust. Read SEC document |
| November 06, 2018 Filed Nov 7, 2018 22:02 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 19,270 | $37.00 | $712,990.00 |
DisclosureSEC source: 0001209191-18-057614 · doc4.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,370,480 F1 · ownership.nature: Shares are held by the Kim Blickenstaff Revocable Trust. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 22:49 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantStock Options · Derivative | 200,000 | $0.00 Strike: $18.86 | $0.00 |
DisclosureSEC source: 0001209191-18-038170 · doc4.xml · derivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires not disclosed F1 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. F2 · derivative.exercise_date: All shares subject to the option will vest as to 50% on 6/14/2019 and the remainder in 12 equal monthly installments thereafter F3 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 00:24 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionSeries B Warrants · Derivative | 285,700 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001209191-18-025269 · doc4.xml · derivative · entry 3 BLICKENSTAFF KIM D · CIK 0001238913 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 285,700 shares Expires 2018-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 00:24 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 132,444 | $7.55 | $999,952.20 |
DisclosureSEC source: 0001209191-18-025269 · doc4.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,389,750 F1 · kind: The transaction reflects the cashless exercise of Series B warrants to purchase common stock, at a strike price of $3.50 and a closing market price on the date of exercise of $7.55. The exercise of the Series B warrants is exempt pursuant to Rule 166-3. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 00:24 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 285,700 | $3.50 | $999,950.00 |
DisclosureSEC source: 0001209191-18-025269 · doc4.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,522,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reflects the cashless exercise of Series B warrants to purchase common stock, at a strike price of $3.50 and a closing market price on the date of exercise of $7.55. The exercise of the Series B warrants is exempt pursuant to Rule 166-3. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 21:52 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | PurchaseCommon Stock | 750,000 | $2.00 | $1,500,000.00 |
DisclosureSEC source: 0001209191-18-009597 · doc4.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,236,494 F1 · date: The reporting person has committed to purchase shares in connection with the Company's underwritten registered public offering of common stock. F2 · balance_after: The amount of securities beneficially owned following the reported transactions reflects the 10 for 1 reverse stock split of the Issuer's issued and outstanding common stock which was effective on October 9, 2017. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 22:54 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | PurchaseSeries B Warrants to Purchase Common Stock · Derivative | 285,700 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001209191-17-057210 · doc4.xml · derivative · entry 3 BLICKENSTAFF KIM D · CIK 0001238913 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 285,700 Underlying: Common Stock · 285,700 shares Expires 2018-04-17 F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010 Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 22:54 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | PurchaseSeries A Warrants to Purchase Common Stock · Derivative | 285,700 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001209191-17-057210 · doc4.xml · derivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 285,700 Underlying: Common Stock · 285,700 shares Expires 2022-10-17 F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010 Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 22:54 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | PurchaseCommon Stock | 285,700 | $3.50 | $999,950.00 |
DisclosureSEC source: 0001209191-17-057210 · doc4.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 486,494 F1 · date: The reporting person has committed to purchase shares in connection with the Company's underwritten registered public offering of common stock. F2 · balance_after: The amount of securities beneficially owned following the reported transactions reflects the 10 for 1 reverse stock split of the Issuer's issued and outstanding common stock which was effective on October 9, 2017. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010 Read SEC document |
| May 17, 2017 Filed May 18, 2017 20:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantStock Options · Derivative | 315,000 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001209191-17-033628 · doc4.xml · derivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,000 Underlying: Common Stock · 315,000 shares Expires not disclosed F1 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. F2 · derivative.exercise_date: All shares subject to the option will vest as to 25% on 5/17/2018 and the remainder in 36 equal monthly installments thereafter. F3 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| March 23, 2017 Filed Mar 24, 2017 00:28 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | PurchaseCommon Stock | 1,600,000 | $1.25 | $2,000,000.00 |
DisclosureSEC source: 0001209191-17-022685 · doc4.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,007,939 F1 · date: The reporting person has committed to purchase shares in connection with the Company's underwritten registered public offering of common stock. Read SEC document |
| March 23, 2017 Filed Mar 29, 2017 21:34 UTC Amendment | TANDEM DIABETES CARE INC TNDM · Entity 4682 | PurchaseCommon Stock | 1,600,000 | $1.25 | $2,000,000.00 |
DisclosureSEC source: 0001209191-17-023562 · doc4a.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,007,939 F1 · date: The reporting person has committed to purchase shares in connection with the Company's underwritten registered public offering of common stock. F2 · ownership.direct: This amendment is being filed to reflect correctly the total amount of securities beneficially owned indirectly which was inadvertently reported as total amount of securities beneficially owned directly. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:42 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 6,228 | Not disclosed Strike: $58.89 | Not disclosed |
DisclosureSEC source: 0001209191-16-143375 · doc4.xml · derivative · entry 8 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,228 shares Expires 2026-06-22 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:42 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 6,284 | Not disclosed Strike: $55.45 | Not disclosed |
DisclosureSEC source: 0001209191-16-143375 · doc4.xml · derivative · entry 7 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,284 shares Expires 2025-06-16 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:42 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 9,584 | Not disclosed Strike: $38.89 | Not disclosed |
DisclosureSEC source: 0001209191-16-143375 · doc4.xml · derivative · entry 6 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,584 shares Expires 2024-06-27 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:42 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 12,232 | Not disclosed Strike: $24.60 | Not disclosed |
DisclosureSEC source: 0001209191-16-143375 · doc4.xml · derivative · entry 5 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,232 shares Expires 2023-06-28 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:42 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $23.74 | Not disclosed |
DisclosureSEC source: 0001209191-16-143375 · doc4.xml · derivative · entry 4 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2022-07-16 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:42 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 60,000 | Not disclosed Strike: $5.50 | Not disclosed |
DisclosureSEC source: 0001209191-16-143375 · doc4.xml · derivative · entry 3 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2021-07-15 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:42 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 34,500 | Not disclosed Strike: $2.21 | Not disclosed |
DisclosureSEC source: 0001209191-16-143375 · doc4.xml · derivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,500 shares Expires 2020-06-30 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:42 UTC | MEDIVATION, INC. MDVN · Entity 181987 | OtherCommon Stock | 43,242 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-143375 · doc4.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F2 · shares: Includes 2,972 unvested shares subject to a restricted stock award. F1 · price: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. Read SEC document |
| September 21, 2016 Filed Sep 26, 2016 16:47 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,500 | $0.00 Strike: $2.21 | $0.00 |
DisclosureSEC source: 0001209191-16-142811 · doc4.xml · derivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,500 Underlying: Common Stock · 25,500 shares Expires 2020-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.